Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course ofmetabolic inflammation

Osteoarthritis and Cartilage

Volumn 21, Issue 12, 2013, Pages 1813-1823

  Opoka Winiarska, V ^a   Jurecka, A ^b,c   Emeryk, A ^a   Tylki Szymanska A ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c UNIVERSITY OF GDA SK   (Poland)

Author keywords

Anti TNF; Dysostosis multiplex; Metabolic inflammation; Mucopolysaccharidosis; Osteoimmunology

Indexed keywords

ADALIMUMAB; CATHEPSIN K; CERTOLIZUMAB PEGOL; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; CYTOTOXIC AGENT; DENOSUMAB; ETANERCEPT; GENISTEIN; GOLIMUMAB; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; LIPOPOLYSACCHARIDE BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MATRIX METALLOPROTEINASE; MISOPROSTOL; MORPHOGEN; MYELOID DIFFERENTIATION FACTOR 88; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PROTON PUMP INHIBITOR; TOFACITINIB; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHROPATHY; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; BONE DESTRUCTION; BONE DISEASE; BONE REMODELING; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DISEASE MODEL; EXTERNAL BEAM RADIOTHERAPY; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; HYPERTENSION; IMMUNOLOGY; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; KINESIOTHERAPY; MAROTEAUX LAMY SYNDROME; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; OSTEOIMMUNOLOGY; OSTEOPENIA; PATHOPHYSIOLOGY; PEPTIC ULCER; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKELETON; SYNOVIUM; TOXICITY; TUBERCULOSIS;

ANTI-TNF; DYSOSTOSIS MULTIPLEX; METABOLIC INFLAMMATION; MUCOPOLYSACCHARIDOSIS; OSTEOIMMUNOLOGY;

BONE DISEASES; CARTILAGE, ARTICULAR; DYSOSTOSES; GLYCOSAMINOGLYCANS; HUMANS; JOINT DISEASES; MUCOPOLYSACCHARIDOSES; MUCOPOLYSACCHARIDOSIS I; MUCOPOLYSACCHARIDOSIS II; MUCOPOLYSACCHARIDOSIS VI; MUCOPOLYSACCHARIDOSIS VII; SYNOVITIS;

EID: 84888865969     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2013.08.001     Document Type: Review

References (79)

1. Burton B.K., Giugliani R. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls. Eur J Pediatr 2012, 171:631-639.
2. Giugliani R., Federhen A., Rojas M.V., Vieira T., Artigalas O., Pinto L.L., et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol 2010, 33:589-604.
3. Hendriksz C.J., Giugliani R., Harmatz P., Lampe C., Martins A.M., Pastores G.M., et al. Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). JInherit Metab Dis 2013, 36:373-384.
4. de Ru M.H., Teunissen Q.G., van der Lee J.H., Beck M., Bodamer O.A., Clarke L.A., et al. Capturing phenotypic heterogeneity in MPS I: results of an international consensus procedure. Orphanet J Rare Dis 2012, 7:22.
5. Valstar M.J., Neijs S., Bruggenwirth H.T., Olmer R., Ruijter G.J., Wevers R.A., et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 2010, 68:876-887.
6. Golda A., Jurecka A., Tylki-Szymanska A. Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). Int J Cardiol 2011, 158:6-11.
7. Alliston T. Chondroitin sulfate and growth factor signaling in the skeleton: possible links to MPS VI. JPediatr Rehabil Med 2010, 3:129-138.
8. Aldenhoven M., Sakkers R.J., Boelens J., de Koning T.J., Wulffraat N.M. Musculoskeletal manifestations of lysosomal storage disorders. Ann Rheum Dis 2009, 68:1659-1665.
9. Oussoren E., Brands M.M., Ruijter G.J., der Ploeg A.T., Reuser A.J. Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options. Biochim Biophys Acta 2011, 1812:1542-1556.
10. Geusens P., Lems W.F. Osteoimmunology and osteoporosis. Arthritis Res Ther 2011, 13:242.
11. Okamoto K., Takayanagi H. Regulation of bone by the adaptive immune system in arthritis. Arthritis Res Ther 2011, 13:219.
12. Jones D., Glimcher L.H., Aliprantis A.O. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. JClin Invest 2011, 121:2534-2542.
13. Raggatt L.J., Partridge N.C. Cellular and molecular mechanisms of bone remodeling. JBiol Chem 2010, 285:25103-25108.
14. Gandhi N.S., Mancera R.L. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 2008, 72:455-482.
15. Simonaro C.M., Haskins M.E., Schuchman E.H. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001, 81:1319-1328.
16. Wang J.Y., Roehrl M.H. Glycosaminoglycans are a potential cause of rheumatoid arthritis. Proc Natl Acad Sci U S A 2002, 99:14362-14367.
17. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
18. Navab M., Gharavi N., Watson A.D. Inflammation and metabolic disorders. Curr Opin Clin Nutr Metab Care 2008, 11:459-464.
19. Furuhashi M., Ishimura S., Ota H., Miura T. Lipid chaperones and metabolic inflammation. Int J Inflam 2011, 2011:642612.
20. DiRosario J., Divers E., Wang C., Etter J., Charrier A., Jukkola P., et al. Innate and adaptive immune activation in the brain of MPS IIIB mouse model. JNeurosci Res 2009, 87:978-990.
21. Killedar S., DiRosario J., Divers E., Popovich P.G., McCarty D.M., Fu H. Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response. JNeuroinflammation 2010, 7:39.
22. Tessitore A., Pirozzi M., Auricchio A. Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI. Pathogenetics 2009, 2:4.
23. Simonaro C.M., Ge Y., Eliyahu E., He X., Jepsen K.J., Schuchman E.H. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 2010, 107:222-227.
24. Simonaro C.M., D'Angelo M., Haskins M.E., Schuchman E.H. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005, 57:701-707.
25. Simonaro C.M., D'Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 2008, 172:112-122.
26. Yasuda Y., Kaleta J., Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 2005, 57:973-993.
27. Nuttall J.D., Brumfield L.K., Fazzalari N.L., Hopwood J.J., Byers S. Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI. Calcified Tissue Int 1999, 65:47-52.
28. Wilson S., Hashamiyan S., Clarke L., Saftig P., Mort J., Dejica V.M., et al. Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities. Am J Pathol 2009, 175:2053-2062.
29. Chiaro J.A., Baron M.D., Del Alcazar C.M., O'Donnell P., Shore E.M., Elliott D.M., et al. Postnatal progression of bone disease in the cervical spines of mucopolysaccharidosis I dogs. Bone 2013, 55:78-83.
30. de Oliveira P.G., Baldo G., Quoos Mayer F., Martinelli B., Meurer L., Giugliani R., et al. Characterization of joint disease in mucopolysaccharidosis type I mice. Int J Exp Pathol 2013.
31. Silveri C.P., Kaplan F.S., Fallon M.D., Bayever E., August C.S. Hurler syndrome with special reference to histologic abnormalities of the growth plate. Clin Orthop Relat Res 1991, 305-311.
32. McClure J., Smith P.S., Sorby-Adams G., Hopwood J. The histological and ultrastructural features of the epiphyseal plate in Morquio type A syndrome (mucopolysaccharidosis type IVA). Pathology 1986, 18:217-221.
33. Kalteis T., Schubert T., Caro W.C., Schroder J., Luring C., Grifka J. Arthroscopic and histologic findings in Morquio's syndrome. Arthroscopy 2005, 21:233-237.
34. Metcalf J.A., Zhang Y., Hilton M.J., Long F., Ponder K.P. Mechanism of shortened bones in mucopolysaccharidosis VII. Mol Genet Metab 2009, 97:202-211.
35. Eliyahu E., Wolfson T., Ge Y., Jepsen K.J., Schuchman E.H., Simonaro C.M. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. PloS One 2011, 6:e22447.
36. Abreu S., Hayden J., Berthold P., Shapiro I.M., Decker S., Patterson D., et al. Growth plate pathology in feline mucopolysaccharidosis VI. Calcified Tissue Int 1995, 57:185-190.
37. Rowan D.J., Tomatsu S., Grubb J.H., Montano A.M., Sly W.S. Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII. JInherit Metab Dis 2013, 36:235-246.
38. Tomatsu S., Okamura K., Maeda H., Taketani T., Castrillon S.V., Gutierrez M.A., et al. Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. JInherit Metab Dis 2005, 28:187-202.
39. Polgreen L.E., Miller B.S. Growth patterns and the use of growth hormone in the mucopolysaccharidoses. JPediatr Rehabil Med 2010, 3:25-38.
40. Rozdzynska A., Tylki-Szymanska A., Jurecka A., Cieslik J. Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II. Acta Paediatr 2011, 100:456-460.
41. Tylki-Szymanska A., Rozdzynska A., Jurecka A., Marucha J., Czartoryska B. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase). Mol Genet Metab 2010, 99:10-17.
42. Byers S., Nuttall J.D., Crawley A.C., Hopwood J.J., Smith K., Fazzalari N.L. Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI. Bone 1997, 21:425-431.
43. Norrdin R.W., Simske S.J., Gaarde S., Schwardt J.D., Thrall M.A. Bone changes in mucopolysaccharidosis VI in cats and the effects of bone marrow transplantation: mechanical testing of long bones. Bone 1995, 17:485-489.
44. Hinek A., Wilson S.E. Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 2000, 156:925-938.
45. Clarke L.A. Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator. Rheumatology 2011, 50(Suppl 5):v13-v18.
46. Goldring M.B., Marcu K.B. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 2009, 11:224.
47. Gatto F., Redaelli D., Salvade A., Marzorati S., Sacchetti B., Ferina C., et al. Hurler disease bone marrow stromal cells exhibit altered ability to support osteoclast formation. Stem Cells Dev 2012, 21:1466-1477.
48. Monroy M.A., Ross F.P., Teitelbaum S.L., Sands M.S. Abnormal osteoclast morphology and bone remodeling in a murine model of a lysosomal storage disease. Bone 2002, 30:352-359.
49. Aaronson D.S., Horvath C.M. Aroad map for those who don't know JAK-STAT. Science 2002, 296:1653-1655.
50. Walker J.G., Smith M.D. The Jak-STAT pathway in rheumatoid arthritis. JRheumatol 2005, 32:1650-1653.
51. Norrdin R.W., Moffat K.S., Thrall M.A., Gasper P.W. Characterization of osteopenia in feline mucopolysaccharidosis VI and evaluation of bone marrow transplantation therapy. Bone 1993, 14:361-367.
52. Polgreen L.E., Thomas W., Fung E., Viskochil D., Stevenson D.A., Steinberger J., et al. Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI. JClin Densitom 2013, pii: S1094-6950(13)00041-3. http://dx.doi.org/10.1016/j.jocd.2013.03.004.
53. Rigante D., Caradonna P. Secondary skeletal involvement in Sanfilippo syndrome. QJM 2004, 97:205-209.
54. Fung E.B., Johnson J.A., Madden J., Kim T., Harmatz P. Bone density assessment in patients with mucopolysaccharidosis: a preliminary report from patients with MPS II and VI. JPediatr Rehabil Med 2010, 3:13-23.
55. Clarke L.A., Winchester B., Giugliani R., Tylki-Szymanska A., Amartino H. Biomarkers for the mucopolysaccharidoses: discovery and clinical utility. Mol Genet Metab 2012, 106:395-402.
56. Schett G. Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009, 11:210.
57. Wright H.L., Moots R.J., Bucknall R.C., Edwards S.W. Neutrophil function in inflammation and inflammatory diseases. Rheumatology 2010, 49:1618-1631.
58. Valayannopoulos V., Wijburg F.A. Therapy for the mucopolysaccharidoses. Rheumatology 2011, 50(Suppl 5):v49-v59.
59. Harmatz P. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures. Turkish J Pediatr 2010, 52:443-449.
60. Tylki-Szymanska A., Marucha J., Jurecka A., Syczewska M., Czartoryska B. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. JInherit Metab Dis 2010, 33:151-157.
61. Tylki-Szymanska A., Jurecka A., Zuber Z., Rozdzynska A., Marucha J., Czartoryska B. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: 3-year follow-up. Acta Paediatr 2012, 101:e42-e47.
62. Crawley A.C., Niedzielski K.H., Isaac E.L., Davey R.C., Byers S., Hopwood J.J. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. JClin Invest 1997, 99:651-662.
63. Turbeville S., Nicely H., Rizzo J.D., Pedersen T.L., Orchard P.J., Horwitz M.E., et al. Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. Mol Genet Metab 2011, 102:111-115.
64. Fan J.Q. Acounterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol Chem 2008, 389:1-11.
65. Piotrowska E., Jakobkiewicz-Banecka J., Baranska S., Tylki-Szymanska A., Czartoryska B., Wegrzyn A., et al. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 2006, 14:846-852.
66. Piotrowska E., Jakobkiewicz-Banecka J., Maryniak A., Tylki-Szymanska A., Puk E., Liberek A., et al. Two-year follow-up of Sanfilippo disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 2011, 17:CR196-CR202.
67. Piotrowska E., Jakóbkiewicz-Banecka J., Tylki-Szymanska A., Liberek A., Maryniak A., Malinowska M., et al. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open label, pilot study in 10 pediatric patients. Curr Ther Res Clin Exp 2008, 69:166-179.
68. Jakobkiewicz-Banecka J., Piotrowska E., Narajczyk M., Baranska S., Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. JBiomed Sci 2009, 16:26.
69. Wegrzyn G., Jakobkiewicz-Banecka J., Gabig-Ciminska M., Piotrowska E., Narajczyk M., Kloska A., et al. Genistein: a natural isoflavone with a potential for treatment of genetic diseases. Biochem Soc Trans 2010, 38:695-701.
70. Wegrzyn A. Gene expression-targeted isoflavone therapy. IUBMB Life 2012, 64:307-315.
71. Malinowska M., Wilkinson F.L., Langford-Smith K.J., Langford-Smith A., Brown J.R., Crawford B.E., et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010, 5:e14192.
72. Marucha J., Tylki-Szymanska A., Jakobkiewicz-Banecka J., Piotrowska E., Kloska A., Czartoryska B., et al. Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT). Am J Med Genet A 2011, 155A:2257-2262.
73. Giugliani R., Harmatz P., Wraith J.E. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007, 120:405-418.
74. Vonkeman H.E., van de Laar M.A. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 2010, 39:294-312.
75. Chu W.M. Tumor necrosis factor. Cancer Lett 2013, 328:222-225.
76. Muenzer J., Wraith J.E., Clarke L.A. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009, 123:19-29.
77. Karmakar S., Kay J., Gravallese E.M. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am 2010, 36:385-404.
78. Deodhar A., Dore R.K., Mandel D., Schechtman J., Shergy W., Trapp R., et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2010, 62:569-574.
79. Ghoreschi K., Jesson M.I., Li X., Lee J.L., Ghosh S., Alsup J.W., et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). JImmunol 2011, 186:4234-4243.